Carterra, leveraging its high-throughput surface plasmon resonance (HT-SPR) technology, is positioned to benefit from the surge in wet lab work fueled by AI’s role in drug discovery. Recently highlighted in a William Blair white paper, “From Code to Clinic,” analysts Matthew Larew and Jacob Krahenbuhl emphasized that despite AI’s capabilities in computational research, physical wet lab experiments remain essential. They designated Carterra as a leading technology provider for antigen preparation, antibody optimization, and binding characterization, suggesting that the wet lab’s importance is often overstated. Carterra’s innovative HT-SPR technology enhances drug discovery workflows by accommodating the vast data outputs generated by AI. The company’s latest platform, Vega, which launched in 2026, dramatically increases the screening capacity for small molecules, setting new industry standards. Acknowledged by William Blair, Carterra continues to innovate to accelerate drug development and improve clinical success rates.
Source link
